Related Experiment Video
Updated: Jul 19, 2026

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial
Weiwei Wang1, Xia Liu, Jing Zhao
1Institute of Developmental Biology, School of Life Science, Shandong University, Jinan 250100, China.
Abstract:
To understand the effects of a novel butyrolactone derivative, 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-one (3BDO), on the apoptosis of vascular endothelial cells (VECs), we exposed 3BDO (20-60 microg/ml) to VECs deprived of serum and FGF-2 for 24 and 48 h, respectively. The results showed that 3BDO (20-60 microg/ml) increased VEC viability and inhibited VEC apoptosis induced by deprivation of serum and FGF-2 in a very weak dose-dependent manner. During this process, integrin beta4 expression was depressed, but the level of reactive oxygen species (ROS) was not changed. The data suggested that 3BDO (20-60 microg/ml) could inhibit VEC apoptosis and suppress integrin beta4 expression, but it could not depress the ROS level induced by deprivation of serum and FGF-2.
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
The Intrinsic Apoptotic Pathway
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Regulation of Angiogenesis and Blood Supply